Drug Profile
Bevacizumab ophthalmic - Outlook Therapeutics
Alternative Names: bevacizumab gamma; bevacizumab-vikg; LYTENAVA; ONS-5010Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Outlook Therapeutics
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Wet age-related macular degeneration
- Phase III Branch retinal vein occlusion; Diabetic macular oedema
Most Recent Events
- 22 Mar 2024 Outlook Therapeutics received positive feedback from The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of wet age-related macular degeneration (wet AMD) in the EU
- 24 Jan 2024 Outlook Therapeutics initiates phase III NORSE EIGHT trial for Wet age-related macular degeneration (Intravitreous) in USA (NCT06190093)
- 23 Jan 2024 Outlook Therapeutics receives written agreement from the US FDA under Special Protocol Assessment for the NORSE EIGHT clinical trial protocol